Parkinson's Disease Market is expected to reach a valuation of US$ 17.12 Billion by 2033 | FMI Study

 In fiscal year 2023, the global Parkinson's Disease Market is expected to be worth US$ 5.41 billion, up from US$ 4.82 billion in fiscal year 2022. The global market is expected to grow at a 12.2% CAGR between 2023 and 2033, reaching a value of US$ 17.12 billion by the end of 2033.



For more information: https://www.futuremarketinsights.com/reports/parkinsons-disease-market

According to the Parkinson's Foundation, males are more likely than women to have Parkinson's disease. Men were discovered to have a higher occurrence, and their risk was shown to be around 1.5 times higher than that of women. Most often, those over 60 are affected by it. A number of the symptoms of Parkinson's disease can be alleviated with medication and other therapy methods including exercise. Drugs including safinamide, levodopa, benztropine, pramipexole, and selegiline are important therapy options for Parkinson's disease patients.

Increasing pharmacological approvals for Parkinson's disease treatment are anticipated to stimulate market expansion throughout the anticipated time frame. For instance, the Japanese pharmaceutical and biotechnology company Kyowa Kirin Co., Ltd. reported in August 2019 that the NOURIANZ medication has received FDA clearance in the United States (istradefylline). It is used as an additional therapy to levodopa/carbidopa in adult patients with Parkinson's disease who are having 'OFF' episodes (PD).

When a patient's medications are not working properly, it can cause an increase in Parkinson's disease (PD) symptoms such as tremor and walking difficulties, which is known as a "off episode." NOURIANZ (istradefylline), an adenosine A2A receptor antagonist, is used to treat Parkinson's disease in the United States. The medication provides Parkinson's disease patients with a new non-dopaminergic once-daily oral treatment option. Such advancements are expected to drive global growth in the Parkinson's disease market between 2023 and 2033.

Key Takeaways from the Market Study

  • The global Parkinson's disease market is currently worth more than US$ 4.82 Billion.
  • In 2023, the Carbidopa-levodopa segment by drug class type is expected to take the dominant market share of 32%.
  • In 2023, considering the age type, the adult segment is predicted to gain a 21% market share.
  • The North American market for Parkinson's disease is predicted to grow with a steady CAGR of 12.5% from 2023-2033.
  • The APAC for Parkinson's disease is expected to grow with a steady CAGR of 12% during 2023-2033.

“The market is anticipated to expand as more drugs are approved for the treatment of Parkinson's disease and as there is a robust pipeline of novel medications being developed for the condition.” comments a Future Market Insights analyst.

Competitive Landscape

Some of the top players in the global Parkison’s disease market are:

  • Sunovion Pharmaceuticals
  • Adamas Pharmaceuticals
  • Neurocrine Biosciences
  • Supernus Pharmaceuticals
  • Alectos Therapeutics
  • Kyowa Kirin
  • AbbVie
  • Integrative Research Laboratories AB
  • Annovis Bio Inc.
  • Cerevel Therapeutics
  • Biogen Inc.
  • Amneal Pharmaceuticals

Some of the recent developments in this domain are:

  • Biogen Inc. and Alectos Therapeutics signed an agreement in June 2022 to develop and market GBA2 inhibitors (AL01811), a possible therapy for Parkinson's disease patients. This agreement grants Biogen worldwide rights to research, manufacture, and commercialize AL01811. They think they will be well-suited to assist bring AL01811 to patients who need it by combining Alectos' experience in small-molecule therapies with Biogen's worldwide development expertise in Parkinson's disease. They are indeed energized by the prospect of using Biogen's commercial skills to raise the standard of treatment in Parkinson's disease as well as movement disorders in general.

Key Segments Covered In The Parkinson's Disease Market Report

Parkinson's Disease Market By Type:

  • Juvenile Parkinson Disease
  • Young-Onset Parkinson’s Disease
  • Idiopathic Parkinson Disease

Parkinson's Disease Market By Age:

  • Adult
  • Pediatric

Parkinson's Disease Market By Diagnosis:

  • CT Scan
  • MRI Scan
  • DaTSCAN-SPECT scan
  • PET Scan

Parkinson's Disease Market By Drug Class:

  • Carbidopa-Levodopa
  • Carbidopa-Levodopa Infusion
  • Dopamine Agonists
  • Monoamine Oxidase B Inhibitors
  • Catechol O-Methyltransferase Inhibitors
  • Anticholinergics
  • Amantadine

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research pr
Read more

Companion Diagnostics Market Recent Trends, Dynamic Innovation in Technology & Insights 2032

Image
  The global Companion Diagnostics Market is expected to generate approximately US$ 5152.064939 million by 2032, up from US$ 2452.653722 million in 2022, at a CAGR of 7.1% during the forecast period. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Companion Diagnostics market. To read more about this report, visit @ https://www.futuremarketinsights.com/reports/companion-diagnostics-market FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Companion Diagnostics market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision. Over the past decade, healthcare sector has been expanding remarkably, followi
Read more

Hospital Consumables Market is expected to reach valuation of US$ 853.2 Billion | FMI

  According to Future Market Insights' newly released Hospital Consumables market analysis report, global Hospital Consumables market sales in 2021 are expected to be US$ 346 billion. The estimated market growth of 12.5% between 2022 and 2032 is expected to be much greater than the previous trend. The consumables market is estimated to have a total revenue opportunity of US$ 853.2 billion. The increase in chronic diseases, medical operations, and the expanding older population are driving market expansion. To learn more about this report @ https://www.futuremarketinsights.com/reports/hospital-consumables-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Hospital Consumables market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Hospita
Read more